Key Takeaways
- Q1 profit fell sharply, but the story is investment, not deterioration: Net profit dropped to ₹22.49 crores from ₹259.9 crores YoY, driven by a deliberate step-up in R&D expensing, depreciation, and a one-off product-mix shift toward lower-margin civilian work.
- Management gave its first-ever 3-year revenue visibility: A ~₹1,000 crores order book already covers most of the ~₹1,100 crores target, underpinning a stated ~25% CAGR commitment.
- The product pipeline is now a 5-year bet: A wide range of SDRs, iDEX projects, and SATCOM terminals completed development in FY26, with trials starting next month; management expects these to drive the next growth cycle.
- Margins are a black box by design: Management declined all requests for product-level margin, EBITDA guidance, or capacity utilization, citing competitive sensitivity and a wide product mix.
- What to watch next quarter: Whether iDEX trials convert to orders, the pace of execution on the NSIL ground-station contract, and any progress on the Imeds strategic-investor process.
The Q1 Profit Reset
- Revenue fell on order timing, not demand loss: Revenue declined to ₹221.35 crores from ₹248.48 crores because orders expected in the year materialized but will be executed over the next 2 to 3 years.
- R&D expensing hit the P&L directly: The company does not capitalize R&D; a ₹7 crores increase in R&D spend flowed straight through the income statement as an investment in future IP.
- Depreciation stepped up with capacity: New capital equipment for capacity building and market segments added another ₹7 crores in depreciation.
- Product mix swung toward civilian margins: In FY25, 70–80% of revenue came from high-margin defense proprietary products with no competition; in FY26, a major portion came from fishing-boat transponders for NSIL, a project of national interest where the company matched L1 pricing, contributing nearly ₹9 crores in reduced profit.
- New facility overheads added cost: The 100,000 sq ft R&D facility in ACT added approximately ₹5 crores in overheads, while transponder-related manufacturing added ₹5 crores and civilian low-margin work added another ₹5 crores.
- Receivables stretched but secure: Receivables extended to 4–5 months due to inter-ministerial government procedural delays; some received on March 31, more in May–June, and management states nothing will become a bad debt.
- Financial charges rose with the order book: Large orders required performance bank guarantees and 100% advance bank guarantees, increasing financial expenses by ~₹2.6 crores; sanctioned limits from Canara Bank and SBI total ~₹250 crores with significant headroom.
Dr. Abburi Vidyasagar: "In defense sector it's very difficult to exactly, know, expect or you know, the performance based on the sales revenue and profit quarter by quarter or year on year, as the procurement cycle for defense itself is slightly different from what for the civilian applications."
The 3-Year Revenue Visibility
- First-ever multi-year visibility: Management stated that for the first time in company history, there is visibility for the next 3 years, with a ~25% CAGR described as "very, very likely."
- Year-by-year path laid out: Approximately ₹300 crores in year 1, ₹375–400 crores in year 2, and about ₹500 crores in year 3, totaling ~₹1,100 crores over the period.
- Order book already covers the plan: ₹1,000 crores of orders are already on hand against the ~₹1,100 crores target, and this figure excludes SDRs, iDEX projects, and NSIL SATCOM ground stations.
- Rate contract provides baseline: A PNC (rate contract) for the next 3 years has been concluded, with orders on hand of ~₹1,000 crores; SBI has extended credit limits alongside Canara Bank, providing working-capital comfort for execution.
- 5-year ambition extends the story: Management stated the 25% CAGR "should continue for 4th and 5th year also," with a goal to reach turnover of at least ₹1,000 crores by 2030.
Dr. Abburi Vidyasagar: "For the first time in the history of the company, I can confidently say that there is visibility for the next 3 years. It's the first time it's happening now."
Product Pipeline & Trials
- iDEX projects near the finish line: All 5 iDEX projects (3 Army, 2 Navy) are in final stages of development, almost 90% completed, with trials to be offered starting next month; management is "very hopeful and confident" these will translate into good sales revenue as well as profits.
- SDR range developed across the spectrum: A wide range of software-defined radios has been developed across HF to L-band, in handheld/manpack, vehicle, airborne, and shipborne versions, compliant with SCA standards, with frequency hopping and electronic countermeasures; the company expects to be in the top 3 in this segment.
- SDR market opportunity sized at ~₹3,000 crores per annum: Management aims to capture at least 20% share year on year.
- SATCOM terminals positioning: S-band satellite terminals expected to be number 1; other SATCOM terminals in the top 5; a DEAL hub-side order of ~₹100 crores received for highly secured S-band SATCOM terminals for communication on the move for the Indian Army.
- NSIL ground stations as a new vertical: First order to be executed at the new Vijayawada facility: supply of 9 satellite ground stations to NSIL in collaboration with French company Safran, to be built in the next 18 months.
- Ku-band antennas for Navy: Another 3 to 4 months before they are offered for trials.
- RTS rate contract execution: Most orders to be executed in the next 18 months, with a CMC of about ₹160 crores continuing for the next 5 years.
- Space sector optionality: The company is geared up to meet growing requirements for satellite ground stations (both GEO and LEO) and satellite terminals, and is "geared up to make the satellite also," though that depends on NSIL/InSpace/Government direction.
Management: "But where Avantel is differentiated is Avantel has got 5 different competency centers... This is where Avantel stands out with respect to any of the companies, many of the companies."
R&D Investment & Capacity Build
- R&D expensed, not capitalized: Management follows a philosophy of expensing R&D as incurred because "we are not sure when the results will be made— come," making current profitability a direct function of the investment cycle.
- FY27 framed as an investment year: Described as a "crucial year from the R&D perspective"; iDEX and SDR products in various flavors "should all be in place by the time we meet next year AGM," with development completed and most through trials.
- 5-year product readiness achieved: In FY26, the company developed a wide range of products that will meet market requirements for the next 5 years.
- New Vijayawada facility ready: Rights issue funds fully utilized; the unit is likely to be inaugurated in the first week of September, with the NSIL ground-station order as its first execution.
- R&D facility operational: The 100,000 sq ft facility in ACT, inaugurated last year, now houses about 180 engineers dedicated mostly to R&D.
- Energy sector exploration: The company is exploring opportunities to diversify for continuity of order flow and to reach higher revenue levels to qualify for ₹2,000–3,000 crores orders under DPP qualification criteria, though no timeline commitment was given.
Management: "They should all be in place by the time we meet next year AGM. They all should be in place. They should have completed development and most of them have gone through trials."
Imeds Subsidiary
- Certification delays now resolving: Certification took longer than anticipated, but 5 products are now certified (patient monitor, ventilator, CPAP, IPAP, oxygen concentrator), with an industrial license expected next month.
- Flagship product still in design: The "Care at Home" AI- and IoT-integrated mini-ICU product is still in the design phase, with development to be completed in the next one year.
- Strategic-investor process underway: Management is exploring the possibility of finding a strategic investor, potentially taking a majority stake, so Imeds would cease to be an Avantel subsidiary while Avantel retains an investment; this is subject to merchant-banker valuation, Board consideration, and shareholder approval.
- Supply-chain partnerships being built: The marketing team visited China, visited about 15 companies, shortlisted 10, with MOUs with 4–5 companies expected in the next couple of months; contract-manufacturing discussions are ongoing with two US companies (air purifiers, HealthPod) and co-development discussions with a German company (OT lights) and a Japanese company (endoscopic cameras).
Management: "We are exploring the possibility of finding a strategic investor, if required take majority stake, so that it will not be an Avantel subsidiary anymore, but Avantel can have investment."
Margins & Disclosures
- Management declined all margin guidance: When asked for product-level or segment-level margins, competitive landscape, and pricing pressure, management stated "it's very difficult to generalize... Margins cannot be disclosed and it's not in the interest of the company and its shareholders."
- EBITDA guidance also refused: Management stated profitability "all depends upon the competitive landscape and then how others bid, not how we bid" and declined to comment or give guidance.
- Capacity utilization undefined: Management declined to define product capacity utilization, stating the product mix is too wide and infrastructure can support ₹1,000–2,000 crores depending on mix.
- EPS and ROCE expected to improve: Despite the margin black box, management stated EPS and return on capital employed "would only improve year on year for the next 3 years," with FY27 described as a year of investment in R&D and infrastructure.
- Current liabilities healthy: Trade payables are only ₹1.78 crores, all under 30 days; the current ratio is very healthy; most liabilities are bank borrowings and customer advances against bank guarantees.
- Consultancy and professional fees rising: These are described as non-discretionary, compulsory spending for regulatory filings, certifications, and statutory approvals as the company grows.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue CAGR | ~25% compound annual growth rate | Next 3 years |
| Year-1 revenue | Approximately ₹300 crores | FY27 |
| Year-2 revenue | ₹375–400 crores | FY28 |
| Year-3 revenue | Approximately ₹500 crores | FY29 |
| iDEX trials | All 5 projects offered for trials by Indian Navy and Indian Army | Starting next month |
| NSIL ground stations | Supply of 9 satellite ground stations completed | Next 18 months |
| RTS rate contract execution | Most orders executed | Next 18 months |
| RTS CMC | ~₹160 crores CMC | 5 years post-execution |
| SDR and iDEX development completion | All products developed and most through trials | By next AGM |
| Imeds "Care at Home" development | AI- and IoT-integrated mini-ICU completed | Next one year |
| Imeds industrial license | Received | Next month |
| Imeds China MOUs | MOUs with 4–5 companies | Next couple of months |
| EPS and ROCE trajectory | Improve year on year | Next 3 years |
| Turnover target | At least ₹1,000 crores | By 2030 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹221.35 cr, declined from ₹248.48 cr in FY26 |
| Net profit | ₹22.49 cr, declined from ₹259.9 cr in FY26 |
| R&D expenditure increase | ₹7 cr over FY26 |
| Depreciation increase | ₹7 cr over FY26 due to capex |
| Order book | ~₹1,000 cr as of AGM date, including railways, SATCOM ground stations, IMD wind profile radars, and expected DEAL order |
| Revenue visibility (3-year) | ~₹300 cr in year 1, ₹375–400 cr in year 2, ~₹500 cr in year 3, implying ~25% CAGR |
| RTS rate contract basic value | ~₹460 cr, with CMC component of ~₹160 cr over 5 years |
| SDR annual market opportunity | ~₹3,000 cr minimum across Army, Navy, Air Force; target at least 20% share |
| iDEX projects | 5 projects (3 Army, 2 Navy), ~90% completed |
| NSIL satellite ground stations | 9 ground stations, to be built in 18 months, indigenous content >50% |
| Fishing boat transponders supplied | 27,000 units completed; additional order for 5,000 units plus batteries received |
| R&D headcount | ~180 engineers |
| Debt-equity ratio | ~0.1; interest coverage ratio ~11x |
| Sanctioned borrowing limit | ~₹250 cr (fund and non-fund based), against Board permission of ₹350 cr |
| Trade payables | ₹1.78 cr, all less than 30 days; debtors receivable ₹71 cr |